Karyopharm Receives Conditional Marketing Authorization from the European Commission for NEXPOVIO® (selinexor) in Combination with Dexamethasone for the Treatment of Adult Patients with Relapsed and

Mar 29, 2021

-- NEXPOVIO is the First and Only Nuclear Export Inhibitor Authorized by the European Commission -- -- Second European Regulatory Filing Based on Phase 3 BOSTON Data Expected by April 2021 --

Posted by Karyopharm Therapeutics


See all Member News